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Introduction. Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. The prevalence
of hepatitis B (HBV) and C (HCV) in Russia was 7.6 and 5.4 per 100,000, respectively. The aim of this study
was to assess the proportion of HCV and HBV infection among HCC patients, to evaluate associations
between HCV, HBV and stage of HCC and to compare survival of HCC patients by their HBV/HCV status in
the Arkhangelsk region of northwest Russia.
Materials and methods. A retrospective cohort study was conducted using data on all histologically confirmed
HCC cases. Proportions of infected and non-infected HCC cases were calculated by Wilson’s method. The
associations between HBV, HCV and severity of HCC were assessed by Pearson’s Chi-squared test. Survival
data were presented using KaplanMeier curves and median survival. Survival time between the groups was
compared using log-rank tests. Adjustment for potential confounders (sex, age groups, stage of HCC and
cirrhosis stage by Child-Paquet scale) was performed using Cox regression.
Results. There were 583 histologically confirmed HCC cases. The viral status was registered in 311 of patients
with pre-mortem diagnosis, where 124 or 39.9% (95% confidence interval (CI), 34.445.4) had HBV, 54 or
17.4% (95% CI, 13.521.9) had HCV and 16 or 5.1% (95% CI, 3.28.2) were infected with both HBV and
HCV. The median survival rates of patients were 3 months (95% CI, 2.33.8), 3 months (95% CI, 2.03.9) and
1 month (95% CI, 0.00.6) for patients with HBV, HCV and HBV and HCV, respectively. For virus-free
patients, it was 5 months (95% CI, 3.56.5), log-rank test10.74, df3, p0.013. Crude Cox regression
showed increased risk of death for HBV and HBV and HCV groups in comparison with virus-free patients,
and not reaching the level of statistical significance for HCV. After adjustment, the hazard ratios (HRs)
decreased to non-significant levels or even reversed, with only exception for the group of patients infected
with both hepatitis viruses.
Conclusions. We found that more than half of HCC patients were infected with HBV or HCV. The study did
not reveal an association between viral status of HCC patients and stage of HCC. The viral hepatitis may
have an impact on survival of HCC patients.
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H
epatocellular carcinoma (HCC) is the fifth most
common cancer among men and the eighth most
common cancer among women worldwide re-
presenting 6% of all cancers in 2009 (1). Men are affected
more often than women (2). Nearly 630,000 new HCC
cases are registered every year worldwide and 54,000 of
them occur in Europe (3). The overall prevalence of HCC
in Central Europe varies between 1 and 2 per 100,000,
whereas in the northern part of Europe, the prevalence of
HCC is less than 1 per 100,000 (4). In Nordic countries,
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the prevalence of HBV and HCV infection does not
exceed 2% (5). According to the European Associa-
tion for the Study of Liver Diseases, the number of
HCC cases in Europe doubled between 2005 and 2010
(5). Probably, the quality of HCC diagnosis was im-
proved. There is an association between the growth of
viral hepatitis among all age groups and increasing
number of HCC cases.
Mortality from HCC was 3.4 per 100,000 in 2007
worldwide with 77% of deaths occurring in developing
countries (6). In countries with low prevalence of HCC,
such as Norway (0.7 per 100,000), Sweden (1.1 per
100,000) and Finland (0.9 per 100,000), mortality from
HCC varies between 0.5% and 2% of all cancer deaths (5).
In 1994, the International Agency for Research on
Cancer classified hepatitis B (HBV) and C (HCV) viruses
as carcinogens of the first class (7). The proportion of
HCC among all cancers steadily increases in parallel to
the increase in the prevalence of chronic forms of HBV
and HCV (8). The risk for developing HCC among HBV-
and HCV-infected persons is higher than that among
non-infected individuals, particularly among those with
mixed infections (8). Nearly 400 million people worldwide
have chronic HBV infection and 170 million have chronic
HCV infection (9).
In Russia, the proportion of HCC is 4.8% of all cancers
(10). According to the official statistics, the prevalence of
HCC in Russia increased from 3.7 per 100,000 in 2003
to 7.1 per 100,000 in 2010. The mortality from HCC in
Russia was 5.8 per 100,000, while the 1-year survival rate
was 11.5% in 2007 (10).
The prevalence of HBV and HCV in Russia was
reported to be 7.6 and 5.4 per 100,000, respectively, with
about 7% of infected had mixed HBV and HCV infection
in 2009 (10). In 2009, the prevalence of HBV and HCV
in Russia was 7.6 and 5.4 per 100,000, respectively,
with about 7% of infected patients exhibiting mixed
HBV and HCV infection (10). In the Archangelsk region,
the prevalence was 4.8 per 100,000, with the highest level
in the Amurski and Bashkirski regions (14.7 and 11.2 per
100,000) (10).
Given considerable health variations across Russia,
national data may not be applicable to the northwestern
part of the country. Indeed, information about HCC and
its associations with HBV and HCV in northwest Russia
is scarce, although the Arkhangelsk Regional Cancer
Registry (ARCR) contains the data on all cancer cases
providing a unique opportunity for epidemiological
studies. The aim of this study is therefore to assess the
proportion of HCV and HBV infection among HCC
patients, evaluate associations between HCV, HBV and
stage of HCC and to compare survival of HCC patients
by their HBV and HCV status in the Arkhangelsk region
of northwest Russia.
Materials and methods
Study subjects
The Arkhangelsk region is among the largest parts of
the Euro-Arctic Barents region with a population of 1.27
million in 2010 (11). We conducted a retrospective cohort
study using data on all histologically confirmed HCC
cases registered in the ARCR from 2000 to 2008.
Viral hepatitis B and C was diagnosed in the Regional
Arkhangelsk Hospital. The diagnosis was based on the
clinical and laboratory data (blood samples testing
for Hbs or Hbc antigen). All physicians working in the
Arkhangelsk region should regularly report on newly
diagnosed cases of cancer to Arkhangelsk Regional
Oncological Dispensary (AROD) using a standardized
form. From this, the information is manually transferred
to the ARCR. Detailed information about data collection
routines and the information available from the ARCR
have been presented elsewhere (12).
In the Arkhangelsk region, there is no universal
registry for infectious diseases. Data on HBV and HCV
in HCC patients were obtained from medical records at
the AROD. We compared the list of HCC patients with
archive data of the Region Hospital of the Arkhangelsk
region as data from all infected patients were collected
there. Our data were based on the medical cards, case
history and treatment protocols.
Data on date of birth, date of HCC diagnosis, date of
death, age, sex, stage of HCC according to the ICD-10
and cirrhosis stage by Child-Paquet scale were obtained
from the ARCR.
Study subjects were grouped into 4 groups based on
age: B60 years, 6069 years, 7079 years, 80 years and
above. The HCC patients were grouped based on stage
using the WHO recommendations (13). Stage I means a
solid tumour less than 2 cm in diameter, stage II is a solid
tumour exceeding 2 cm in diameter; stage III includes
several forms: IIIA includes solid tumour in the liver less
than 2 cm in diameter with invasive growth into the
vessels or multiple liver tumours, while IIIB includes
metastases of the lymphatic nodes. In this study, stages
IIIA and IIIB were used as one group; stage IV is HCC
with distant metastases (13).
The severity of cirrhosis was evaluated using the Child-
Paquet scale: Child A (mild changes in the liver tissue),
Child B (moderate changes) or Child C (severe changes)
(14). This classification is based on the clinical indicators:
the levels of blood bilirubin, albumin, prothrombin
index, encephalopathy and ascite.
Statistical analyses
Proportions of HCC cases with and without HBV
and HCV were presented with 95% confidence intervals
(CI) calculated using Wilson’s method. The associations
between HBV, HCV and severity of HCC were assessed
Maria Makarova et al.
2
(page number not for citation purpose)
Citation: Int J Circumpolar Health 2013, 72: 20282 - http://dx.doi.org/10.3402/ijch.v72i0.20282
by Pearson’s Chi-squared test. Survival data were pre-
sented using KaplanMeier curves and median survival
with 95% CI. Survival time between the groups was
compared using log-rank tests. Adjustment for potential
confounders (sex, age groups, stage of HCC and cirrhosis
stage by Child-Paquet scale) was performed using Cox
regression. Hazard ratios (HRs) were presented with 95%
CI. All analyses were performed using SPSS software,
version 15.0 (SPSS Inc., Chicago, IL, USA).
The study was approved by the Ethical Committee of
the Northern State Medical University, Arkhangelsk,
Russia on 21 October 2010, protocol number 21/10.
Results
There were 583 histologically confirmed HCC cases
during 20002008. Among them, 211 (36.2%), 92
(15.8%) and 28 (4.8%) patients had HBV, HCV infection
or both forms of viruses, respectively. A total of 214
(36.7%) patients were virus-free. For 38 (6.5%) patients,
information about viral status was not available. A total
of 234 patients (40.1%) were diagnosed at autopsy.
Further analysis of the data was performed for those
where HCC was diagnosed pre-mortem. The flow chart
is shown in Figure 1.
Viral status was registered in 311patients with pre-
mortem diagnosis of viral hepatitis B and C. Among
them, 124 or 39.9% (95% CI: 34.445.4) had HBV, 54 or
17.4% (95% CI: 13.521.9) had HCV and 16 or 5.1%
(95% CI: 3.28.2) were infected with both HBV and
HCV. Thus, the overall proportions of infected and non-
infected patients were 62.3% (95% CI: 56967.6) and
37.6% (95% CI: 32.443.2), respectively.
There were 128 (41.1%) females and 183 (58.9%) males.
The mean age was 70.9 years for women and 71.3 years
for men.
The proportion of patients with and without infection
by basic demographic and clinical characteristics is
shown in Table I. The cirrhosis stage among patients
with HCC was significantly associated with viral status.
Survival curves by viral status are shown in Figure 2.
The median survival of patients was 3 months (95%
CI, 2.33.8), 3 months (95% CI, 2.03.9) and 1 month
(95% CI, 0.00.6) for patients with HBV, HCV and HBV
and HCV, respectively, while virus-free patients had a
median survival of 5 months (95% CI, 3.56.5), log-rank
test10.74, df3, p0.013.
Crude Cox regression showed an increased risk of
death for all virus groups in comparison with virus-
free patients, although not reaching the level of statis-
tical significance for HCV. However, after adjustment
for potential confounders, the HR decreased to non-
significant levels or even reversed, with the only exception
for the group of patients infected with both hepatitis
viruses (Table II).
Discussion
This study is one of the first to investigate the association
of viral hepatitis status and its impact on HCC not only
in northwest Russia but also in the Russia Federation
in general. We found that more than half of HCC patients
in the Arkhangelsk region were infected with viral hepa-
titis B and C. No association was determined between
the viral status of HCC patients and the stage of HCC.
However, viral hepatitis B and C had an impact on
survival of HCC patients.
It has been established that viral hepatitis B and C
activate metabolism and biosynthesis of lipids, which
damages hepatic tissue. Viral infection includes lipogenic
gene expression within hepatic cells that promote carci-
nogenesis (15). The proportion of HCC patients infected
by HBV and HCV in this study constitutes 39.9 and
17.4%, respectively. Earlier regional registry-based stu-
dies report that approximately 4055% of HCC patients
have HBV in anamnesis (16) and that the proportion of
HCV-infected individuals is 2530% (17). Furthermore,
official statistics shows that more than 50% of HCC
patients in Russia are infected with either HBV or HCV
(10,17). The typical habitus of a viral-infected patient
is men of 5259 years, alcohol-abused, smokers, with
specialized secondary education.
The only factor that had uneven distribution among
HCC patients in our study was cirrhosis frequency.
Cirrhosis stage as evaluated by Child-Paquet scale was
based on the calculations of the laboratory tests of the
blood samples, which were unavailable for non-infected
HCC patients. Our study demonstrated that 56.2% of
infected HCC patients had liver lesions due to liver
cirrhosis. We found a large proportion of advanced forms
of liver cirrhosis in virus-infected patients. Child B and
C were 35.5% for HBV, 29.7% for HCV and 31.3% for
HBV and HCV, respectively, while this proportion in
non-infected patients was 12.9%. The cirrhosis is not an
Diagnosis С22.0 – hepatocellular carcinoma according to Arkhangelsk 
Regional Cancer Registry data   
N= 583
Diagnosis С22.0 – hepatocellular 
carcinoma was detected at autopsy 
N=234 (40.1%)
Information about viral status was 
not available 
N=38 (6.5%)
Selected cases for the further analysis
N=311 (53.3%)
Virus free 
patients
N=117
(37.6%) 
HBV patients
N=124
(40.0%)
HCV patients
N=54
(17.4%)
HBV&HCV
patients
N=16
(5.0%)
Fig. 1. Sample description.
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obligatory stage for HCC. Probably, there was under-
estimation of the cirrhosis condition. In the Arkhangelsk
region, the detection of fibre tissue in hepar begun in
2011. The liver cirrhosis among infected is probably a
pre-stage in the development of HCC (8,18).
Since our study is based on the registry data and
information about alcohol consumption, another toxic
factor was not available for the analysis. It might be
supported that cirrhosis was a background condition of
these patients, which was not diagnosed.
We performed subanalysis of survival for this group of
patients. There were 19 cases of death from 61 non-infected
patients with cirrhosis stage 12. Thus, 19 cases of death
were confirmed at autopsy. The cause of death was not
HCC. The causes of deaths among these 19 cases were road
accidents (3 cases), cardiac infarction (9 cases), stroke
(4 cases) and suicides (3 cases). Also, within the frames
of diagnosis C22 (HCC), metastatic liver cancer could
be included. This fact supported the initially large number
of deaths. But there were 11 patients who lived 219
months after the diagnosis was established. The problem of
diagnosing HCC influences the oncological statistics. In
the Arkhangelsk region, there were several misdiagnosed
HCC cases. The clinicians diagnosed metastatic liver
cancer as C22, and such cases were included into the
registry. During autopsy the diagnosis was changed, but
these new data were not registered. The official statistics is
published 23 months before the reports of pathologists
become available leading to some differences between
clinical diagnosis and the diagnosis made by a pathologist.
In our study, there was no association between viral status
and HCC stage. Stages III and IV prevailed both among
virus-free (29.1 and 35.0%, respectively) and infected
patients (25.8 and 42.8%, respectively). The studied
population was comparable to the HCC population as of
Russia, and for the European countries. The probable
explanation is that infected patients are thoroughly
followed up after diagnosis of HBV and/or HCV having
annual radiological examination of the liver. In contrast,
virus-free patients likely have less aggressive tumours are
examined less frequently. It may lead to the development
off the HCC advanced stages. On the contrary, Wo¨rns
et al. demonstrated an association between viral status
and HCC stage (19). According to their data, virus-free
patients have I or II HCC stages (32.6 and 42.8%,
respectively). The results by Sylla et al. also indicate that
more than 60% of infected patients exhibit HCC stages III
or IV stages, while among virus-free patients stage I and II
predominate (46.5 and 31.6%, respectively) (20). The
reason is that viral hepatitis impairs liver cells. Therefore,
HCC develops on the formed pathological substrate of
damaged liver tissue. While virus-free patients have no
pathological changes within liver tissue, stages I and II
prevail. The data about duration of viral hepatitis were not
Table I. Socio-demographic and basic clinical characteristics of HCC patients in the Arkhangelsk region in 20002008 by their
viral status
Proportion of virus-free patients,
% (n117)
Proportion of patients with viral hepatitis, % (n194)
Characteristics HBV (n124) HCV (n54) HBV and HCV (n16) p*
Gender
Male 73 (62.4%) 65 (52.4%) 35 (64.8%) 8 (50.0%) 0.266
Female 44 (37.6%) 59 (47.6%) 19 (35.2%) 8 (50.0%)
Age (years)
B60 25 (21.4%) 20 (16.1%) 5 (9.3%) 5 (31.3%) 0.491
6069 17 (14.5%) 21 (16.9%) 9 (16.7%) 3 (18.8%)
7079 39 (33.3%) 43 (34.7%) 24 (44.4%) 6 (37.5%)
80 and above 36 (30.8%) 40 (32.3%) 16 (29.6%) 2 (12.5%)
HCC stage
Data not available 11 (9.4%) 22 (17.7%) 8 (14.8%) 5 (31.3%)
I 15 (12.8%) 8 (6.5%) 5 (9.3%) 1 (6.3%) 0.117
II 16 (13.7%) 10 (8.1%) 2 (3.7%) 0 (0.0%)
III 34 (29.1%) 34 (27.4%) 14 (25.9%) 2 (12.5%)
IV 41 (35.0%) 50 (40.3%) 25 (26.3%) 8 (50.0%)
Cirrhosis stage
No cirrhosis 65 (55.6%) 45 (36.3%) 33 (61.1%) 7 (43.8%) B0.0001
Child A 37 (31.6%) 35 (28.2%) 5 (9.3%) 4 (25.0%)
Child B 14 (12.0%) 26 (21.0%) 9 (16.7%) 3 (18.8%)
Child C 1 (0.9%) 18 (14.5%) 7 (13.0%) 2 (12.5%)
*Calculated using Pearson’s Chi-squared test.
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available. Patients infected with viral hepatitis B or C had
annual medical examinations, including biochemical
blood analysis and ultrasound hepar examination. Virus-
free patients without evident cancer signs could undergo a
prophylactic medical examination, or visit the doctor if
concerned (e.g. family medical history), or, as mentioned
above, within routine check-ups. Furthermore, we have
investigated the impact of viral infection on patient
survival. In this study, KaplanMeier estimates initially
suggested that viral status might shorten survival of
patients with HCC. The proportion of patients who
survived was 2 times higher among virus-free patients by
the 5th year (22.4% for virus-free vs. 9.5% for HBV; 13.0%
for HCV; 6.1% for HBV and HCV). However, after
adjustment for potential confounders (sex, age groups,
cirrhosis stage, stage of HCC, data of viral hepatitis
diagnostics), the survival of both HBV and HCV infected
HCC patients was similar to the survival of non-infected
patients. Only a small group of 16 HCC patients having
mixed infection of HBV and HCV revealed significantly
poorer prognosis as compared to non-infected in the
adjusted model. This is consistent with the evidence that
viral hepatitis worsens the survival of patients with HCC.
In contrast to our data, some authors have shown that
HCC patients with HBV or HCC monoinfection ex-
hibit survival time up to 3 times shorter compared to
non-infected patients (8,15). The adjustment allows us to
get true data in the researched population. We could
not show this due to the small sample size of this study*
our analysis included only 311 selected patients. Otherwise,
our sample includes all HCC cases in the Arkhangelsk
region.
Fig. 2. Survival of HCC patients in the Arkhangelsk region in 20002008 by their viral status. Data show that non-infected HCC
patients have more survival time compared with patients infected with viral hepatitis B and C virus.
Table II. Crude and adjusted hazard ratio for survival of HCC patients in the Arkhangelsk region in 20002008 by their viral status
95% CI 95% CI
Factors HR crude Lower Upper HR adjusteda Lower Upper
Viral status
Virus-free 1.00 Reference Reference 1.00 Reference Reference
HBV-infected 1.43 1.07 1.91 1.13 0.83 1.53
HCV-infected 1.34 0.93 1.93 1.04 0.71 1.52
HBV- and HCV-infected 1.89 1.09 3.27 2.10 1.16 3.78
aAdjusted for sex, age groups, cirrhosis stage and stage of HCC.
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This retrospective cohort study has several limitations
as it only allows assessing existing data. However, it is
useful for exploring an association between survival of
patients with HCC and viral hepatitis status. HCC is a
rare disease. Moreover, during our study more than 40%
of HCC cases were excluded as cases were diagnosed at
autopsy. Vaktskjold et al. report that ARCR contains
quality data providing estimations of the cancer incidence
in the Arkhangelsk region. The authors also consider that
the data from ARCR may show the true cancer situation
in the Arkhangelsk region (12). ARCR covers all cases of
HCC.
During this study we revealed that the ARCR was
developed for medical purposes. It does not contain
enough specific information for our research aims, includ-
ing information about viral status. Additionally, there is
no common database for viral hepatitis in the Arkhan-
gelsk region. Data about such patients are available
only based on medical records and case histories. The
searching of the listed data (hepatitis status) results in
the data about viral status of 6.5% HCC patients being
missing. It was technically impossible to assess the
influence of potential confounders that are associated
with the outcome of the disease (alcohol consumption,
diabetes status, etc.) (21). Also, we did not assess the
association between type of treatment of viral hepatitis
and the outcome of HCC.
The strength of the study is that it is registry-based,
which includes all cases of HCC for the period 20002008
in the Arkhangelsk region. The ARCR covers all geo-
graphic areas of the Arkhangelsk region. Therefore,
ARCR should reflect the whole situation of HCC in the
Arkhangelsk region.
Oncological diseases play a leading role among causes
of death and invalidity of the population. Understanding
the causes allow us to reduce the morbidity and mortality
of cancer. Many studies have demonstrated that HCC
correlates with viral hepatitis. However, these studies
evaluating the association of HCC and viral infection
were not conducted in most regions of Russia. Moreover,
during our study we revealed another problem  mis-
diagnosis of liver cancer and underestimation of viral
hepatitis B and C. This reflects the quality of medical
services for the population, and, as a result, the quality of
public health of the Arkhangelsk region.
Conclusions
We have found that more than half of the HCC patients
were infected with HBV or HCV. The study did not reveal
an association between the viral status of HCC patients
and the stage of HCC. The viral hepatitis may have an
impact on survival of HCC patients.
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